HLA-B*5701 Typing

Clinical Significance

Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of abacavir therapy.

Specimen Requirements

5.0 mL Whole Blood in a Lavender Top Tube - EDTA

Transport And Storage

7 days Ambient
7 days Refrigerated

Collection Instructions

 

Minimum Volume

3.0 mL Whole Blood

Neonatal Volume

Reference Range:

Refer to Interpretive Results

Test Comments:

Additional testing by Sequence Based Typing (SBT) may be performed when necessary.

Limitations: A negative result does not rule out the risk for ABC HSR and clinical vigilance should be maintained regardless of the result. The frequency of HLA/-B5701 is approximately 8% in Caucasians and 2% in African Americans.

Methodology:

• Polymerase Chain Reaction (PCR)
• Sequence Specific Oligonucleotide Probes (SSO)

Clinical Significance

Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of abacavir therapy.

CPT Coding

81381